NCT00354809已完成2 期
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Morning Administration of GW679769 (10mg and 30 mg) on Polysomnograph Sleep Recordings, Subjective Sleep Assessment, Daytime Cognition and Psychomotor Function in Subjects With Primary Insomnia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 25
- 主要终点
- Comparison of GW679769 and placebo when taken daily in the morning, on the time needed to fall asleep at bedtime on Days 1/2 and 8/9 of treatment, as assessed at a sleep clinic.
研究概览
简要总结
This study is designed to determine whether morning doses of GW679769, taken daily for 1 to 9 days, will promote sleep during the following night without significant post-dose thinking impairment and drowsiness in subjects with primary insomnia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Difficulty going to sleep and/or staying asleep during at least the past 3 months.
- •Insomnia must result in significant distress or impairment in functioning at home, socially or at work.
- •Otherwise good health with no significant or unstable medical disorder including psychiatric, neurological, endocrine, heart, lung or gastrointestinal disorders, drug/alcohol abuse, cognitive impairment, cancer or chronic pain conditions such as arthritis.
排除标准
- •History of other sleep disorders such as sleep apnea or restless leg syndrome; regular sleep habits, including bedtime between 9 PM and midnight, nightshift/rotating shift work, frequent napping or planned travel across >2 time zones.
- •Use to moderate use of nicotine, caffeine and alcoholic products.
结局指标
主要结局
Comparison of GW679769 and placebo when taken daily in the morning, on the time needed to fall asleep at bedtime on Days 1/2 and 8/9 of treatment, as assessed at a sleep clinic.
时间窗: 9 Days
次要结局
- Comparison of GW679769 and placebo on total sleep time and time awake after initial sleep onset on Days 1/2 and 8/9 of treatment, as assessed at a sleep clinic. Daily sleep questionnaires and mental functioning tests on Days 1 and 9 of treatment.(9 Days)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
2 期
Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary InsomniaSleep Initiation and Maintenance DisordersInsomniaNCT00280436GlaxoSmithKline122
已完成
2 期
Study Of GW679769 In Major Depressive DisorderDepressive Disorder, MajorMajor Depressive Disorder (MDD)NCT00102492GlaxoSmithKline356
已完成
2 期
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II DiabetesDyslipidemiasDiabetes Mellitus, Type 2NCT01217112Jazz Pharmaceuticals62
已完成
2 期
A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.AsthmaNCT01499446GlaxoSmithKline669
已完成
不适用
GW679769 In FibromyalgiaDepressive DisorderFibromyalgiaDepressionNCT00264628GlaxoSmithKline8